FENC logo
FENC
Fennec Pharmaceuticals

Expanding Global Supportive Cancer Care Will Unlock Future Opportunities

Published
28 Sep 24
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
US$14.00
38.2% undervalued intrinsic discount
20 Aug
US$8.65
Loading
1Y
48.1%
7D
5.5%

Author's Valuation

US$14.0

38.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates8

Shared on01 May 25
Fair value Increased 74%

Read more

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25
Fair value Decreased 42%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Increased 15%

Read more

Shared on26 Mar 25
Fair value Decreased 6.48%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25
Fair value Increased 3.48%

Read more

Shared on11 Mar 25
Fair value Decreased 3.36%

AnalystConsensusTarget has decreased revenue growth from 48.3% to 31.3% and decreased shares outstanding growth rate from 0.0% to -0.0%.

Read more